Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension

被引：99

作者：

Hsueh, Willa A. ^{[1
]}

Wyne, Kathleen ^{[2
]}

机构：

[1] Methodist Hosp, Res Inst, Diabet Res Ctr, Weill Cornell Med Coll, Houston, TX 77030 USA

[2] Methodist Hosp, Div Diabet Obes & Lipids, Dept Med, Weill Cornell Med Coll, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL HYPERTENSION | 2011年 / 13卷 / 04期

关键词：

CONVERTING ENZYME-INHIBITION; LEFT-VENTRICULAR DYSFUNCTION; CHRONIC HEART-FAILURE; INSULIN-RESISTANCE; BLOOD-PRESSURE; METABOLIC SYNDROME; ADIPOSE-TISSUE; RECEPTOR BLOCKER; RENAL OUTCOMES; RISK-FACTORS;

D O I：

10.1111/j.1751-7176.2011.00449.x

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Activation of the renin-angiotensin-aldosterone system (RAAS) is the primary etiologic event in the development of hypertension in people with diabetes mellitus. Modulation of the RAAS has been shown to slow the progression and even cause regression of the microvascular and macrovascular complications associated with diabetes mellitus. Early pharmacotherapy with agents that decrease RAAS activation in the adipose tissue have had a dramatic impact on the prevalence of diabetes related complications. Recent data show that preventing the development of "angry fat" can prevent not just hypertension but also type 2 diabetes mellitus and its associated complications. This review updates what is known about angry fat and the role of RAAS inhibition in preventing the metabolic sequelae of local RAAS activation. J Clin Hypertens (Greenwich). 2011;13:224-237. (C) 2011 Wiley Periodicals, Inc.

引用

页码：224 / 237

页数：14

共 114 条

[1] Renin receptor expression in human adipose tissue [J].

Achard, Vincent ;

Boullu-Ciocca, Sandrine ;

Desbriere, Raoul ;

Nguyen, Genevieve ;

Grino, Michel .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2007, 292 (01) :R274-R282

[2]

Alberti G., 2006, The IDF consensus worldwide of the metabolic syndrome

[3] Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].

Alberti, KGMM ;

Zimmet, P ;

Shaw, J .

DIABETIC MEDICINE, 2006, 23 (05) :469-480

[4]

[Anonymous], ENDOCRINOL METAB CLI

[5]

Bakhai A, 2008, QJM-INT J MED, V101, P767, DOI 10.1093/qjmed/hcn066

[6] Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy [J].

Bakris, George ;

Burgess, Ellen ;

Weir, Matthew ;

Davidai, Giora ;

Koval, Stephen .

KIDNEY INTERNATIONAL, 2008, 74 (03) :364-369

[7] Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure [J].

Baruch, L ;

Anand, I ;

Cohen, IS ;

Ziesche, S ;

Judd, D ;

Cohn, JN .

CIRCULATION, 1999, 99 (20) :2658-2664

[8] Response to comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e54, 2011) [J].

Wysham, C. H. ;

Kirkman, M. S. .

DIABETES CARE, 2011, 34 (08) :1887-1887

[9] Identification of a Retinal Aldosterone System and the Protective Effects of Mineralocorticoid Receptor Antagonism on Retinal Vascular Pathology [J].

Berka, Jennifer L. Wilkinson ;

Tan, Genevieve ;

Jaworski, Kassie ;

Miller, Antonia G. .

CIRCULATION RESEARCH, 2009, 104 (01) :124-U309

[10] Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial [J].

Beulens, J. W. J. ;

Patel, A. ;

Vingerling, J. R. ;

Cruickshank, J. K. ;

Hughes, A. D. ;

Stanton, A. ;

Lu, J. ;

Thom, S. A. McG ;

Grobbee, D. E. ;

Stolk, R. P. .

DIABETOLOGIA, 2009, 52 (10) :2027-2036

← 1 2 3 4 5 6 7 8 9 10 →